Abivax has been granted a patent for a compound and its metabolites for treating inflammatory diseases. The method involves administering specific compounds to patients suffering from various inflammatory conditions in different organs and systems, including pancreas, kidney, liver, lung, heart, skin, blood vessels, eyes, nervous system, autoimmune diseases, reproductive system, and bone/joints. GlobalData’s report on Abivax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abivax, Cancer treatment biomarkers was a key innovation area identified from patents. Abivax's grant share as of May 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of inflammatory diseases in various organs
A recently granted patent (Publication Number: US11992499B2) discloses a method for treating various inflammatory diseases, disorders, or conditions by administering a specific compound to patients suffering from these ailments. The compound in question is 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine or a pharmaceutically acceptable salt thereof. The inflammatory conditions targeted include those affecting different organs and systems such as the pancreas, kidney, liver, lung, heart, skin, blood vessels, eyes, nervous system, autoimmune diseases, reproductive system, and bone/joints. The method involves administering the compound to patients and monitoring its efficacy in treating the specific inflammatory disease, disorder, or condition.
Furthermore, the patent also covers the use of specific compounds of formula (IV) and formula (I) in treating inflammatory diseases, disorders, or conditions. The method includes administering these compounds to patients suffering from inflammatory ailments and potentially combining them with other medications like JAK-inhibitors or tofacitinib for enhanced therapeutic effects. The patent also includes claims related to measuring the levels of the administered compounds in patient samples, monitoring specific biomarkers like miR-124, and assessing the severity of the inflammatory conditions being treated. Overall, the patent provides a comprehensive approach to treating a wide range of inflammatory diseases, disorders, or conditions using specific compounds and combinations thereof, offering potential advancements in the field of inflammatory disease management.
To know more about GlobalData’s detailed insights on Abivax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
